Lysipressin
Nootropic / cognitive
Cognition, mood, neuroprotection, or neuroplasticity support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Nootropic / neuroactive compound
- Primary mechanism
- Neurotransmitter, neurotrophic, or plasticity pathway modulation
- Primary market use
- Nootropic / cognitive
Pharmacology
- Molecular weight (Da)
- 1056.22
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 9 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in nootropic comparison clusters; track acute vs durable cognitive adaptation.
Notes
Lysipressin acetate (Lysine vasopressin acetate; [Lys8]-Vasopressin acetate) is a neurohypophyseal nonapeptide with dual cardiovascular regulatory activities of peripheral pressor action and central hypotensive action, and it also regulates pain perception in the body. Lysipressin acetate is an Oxytocin Receptor agonist, with a K i value of 10.2 nM for porcine OT receptor. Lysipressin acetate stimulates contraction of rabbit bladder smooth muscle via V1-vasopressin receptor . The central hypoten...